-

Organigram Holdings Inc. Announces Election of Directors

MONCTON, New Brunswick--(BUSINESS WIRE)--Organigram Holdings Inc. (“Organigram” or the “Corporation”) (TSX: OGI) (NASDAQ: OGI) announced today that each of the eight nominees listed in its management information circular dated January 23, 2020 (the “Circular”) was elected as a director of Organigram at the Annual and Special Meeting of Shareholders (the “Meeting”) held on February 25, 2020. The vote was conducted by a show of hands. Detailed results of the votes cast by proxy are set out below:

 

Nominee

   

Votes For

   

% of Votes
For

   

Votes
Withheld

   

% of Votes
Withheld

 
 

Peter Amirault

   

16,616,184

   

97.12

   

492,516

   

2.88

 
 

Greg Engel

   

16,625,303

   

97.18

   

483,397

   

2.83

 
 

Dexter John

   

16,078,699

   

93.98

   

1,030,001

   

6.02

 
 

Geoffrey Machum

   

16,611,530

   

97.09

   

497,170

   

2.91

 
 

Ken Manget

   

16,654,923

   

97.35

   

453,777

   

2.65

 
 

Sherry Porter

   

16,319,053

   

95.39

   

789,647

   

4.62

 
 

Stephen Smith

   

16,642,629

   

97.28

   

466,071

   

2.72

 
 

Derrick West

   

16,600,454

   

97.03

   

508,246

   

2.97

 

The biographies of the Corporation’s directors are set out in the Circular, which is available under the Corporation’s profile on SEDAR at www.sedar.com.

“On behalf of the board, I am delighted to welcome Geoffrey, Ken and Stephen to our team. They bring a robust set of knowledge, skills and experience, and they will complement our board as we continue to grow in a dynamic industry,” said Greg Engel, Organigram’s Chief Executive Officer. “We would also like to thank Mike Bourque, who did not stand for re-election, for his valuable contributions and service to the board over the past few years.”

Following the Meeting, the newly-elected board of directors of the Corporation (the “Board”) re-appointed Peter Amirault as Chairman of the Board. The Board also re-constituted its committees as follows:

  • Audit Committee: Stephen Smith (Chair), Dexter John, Ken Manget, and Derrick West
  • Governance and Nominating Committee: Geoffrey Machum (Chair), Sherry Porter, and Dexter John
  • Compensation Committee: Sherry Porter (Chair), Geoffrey Machum, and Ken Manget
  • Investment Committee: Dexter John (Chair), Ken Manget and Stephen Smith

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics and Trailblazer. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Contacts

For Investor Relations enquiries, please contact:
Amy Schwalm
Vice President, Investor Relations
Amy.Schwalm@organigram.ca
(416) 704-9057

For Media enquiries, please contact:
Ray Gracewood
Senior Vice President, Marketing and Communications
ray.gracewood@organigram.ca
(506) 645-1653

Organigram Holdings Inc.

NASDAQ:OGI

Release Versions
$Cashtags

Contacts

For Investor Relations enquiries, please contact:
Amy Schwalm
Vice President, Investor Relations
Amy.Schwalm@organigram.ca
(416) 704-9057

For Media enquiries, please contact:
Ray Gracewood
Senior Vice President, Marketing and Communications
ray.gracewood@organigram.ca
(506) 645-1653

More News From Organigram Holdings Inc.

Organigram Reports Second Quarter Fiscal 2026 Results

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 (“Q2 Fiscal 2026” or "Q2"). Q2 FISCAL 2026 HIGHLIGHTS Gross Revenue: $93.3 million (-9% year-over-year). Net Revenue: $59.8 million (-9% year-over-year). International Revenue: $6.1 million (0% year-over-year). Adjusted EBITDA2: $0.9 million (-82% year-over-year)....

Organigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 12, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use t...

Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities

TORONTO & BERLIN--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) and Sanity Group GmbH (“Sanity” or “Sanity Group”) jointly announced the successful closing of Organigram’s previously announced acquisition (the “Acquisition”) of Sanity Group, pursuant to the terms of a share purchase agreement dated February 18, 2026 (the “Share Purchase Agreement”). In connection with closing of the Acquisition, a wholly owned subsidiary of the Company acquire...
Back to Newsroom